Nuvation Bio Inc. (NUVB)

3,3250 +0,1050 (+3,26%) In data: 11:11AM EDT. Mercato aperto.

Nuvation Bio Inc.

1500 Broadway
Suite 1401
New York, NY 10036
United States
332 208 6102
https://www.nuvationbio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 51

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. David T. Hung M.D.	Founder, President, CEO & Director	1M	N/D	1958
Dr. Gary Hattersley Ph.D.	Chief Scientific Officer	694,56k	N/D	1967
Dr. David Liu M.D., Ph.D.	Chief Medical Officer	677,15k	N/D	1970
Mr. Moses Makunje CPA	VP of Finance and Principal Accounting & Financial Officer	N/D	N/D	1979
Ms. Stacy Markel	Chief People Officer	N/D	N/D	1965
Dr. David C. Hanley Ph.D.	Chief Technical Operations Officer	586,04k	N/D	1970
Ms. Kerry A. Wentworth	Chief Regulatory Officer	N/D	N/D	1973
Ms. Colleen Sjogren	Chief Commercial Officer	N/D	N/D	1970
Dr. Junyuan Wang Ph.D.	CEO & Co-Founder of AnHeart Therapeutics and Director	N/D	N/D	1973

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Governance aziendale

L'ISS Governance QualityScore di Nuvation Bio Inc. al 1 maggio 2024 è 10. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 7; diritti degli azionisti: 10; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.